Skip to Content
scroll

Anteotech Ltd (ASX: ADO)

Our Q&As are emailed in our Saturday Morning Report, find the answer to this question below.

The Latest Q&A

Question asked

Anteotech Ltd (ASX: ADO)

Hi, I know you don't normally comment on small cap spec stocks but you commented on 1414 degrees last week and I would like your thoughts on ADO as I feel its on the cusp of a major breakout with so many possible areas it could get major deals and be a major player in Batteries and Life science.

Answer

Hi David,

Anteotech Ltd (ADO) is a $65mn early-stage specialty chemicals/materials company trying to commercialise technology that improves lithium-ion batteries, while retaining a smaller life-sciences diagnostics business.

The stocks ~95% drop over recent years demonstrates why we rarely discuss the space, as it can be hard to add value. However, we’re always open to new stocks and ideas. Firstly, the cash position:

  • At June 30 ADO had $11.2m of cash, up sharply from $3.29m at the end of March. However, the improvement was largely funding-driven, i.e. ADO raised roughly $10m from the exercise of listed options, rather than generating the cash internally.

Cash burn remains the key issue. Net operating cash outflow was $1.585m in the June quarter, equivalent to roughly $0.53m per month. On that quarterly burn rate, the $11.2m balance represents around 7 quarters (~21 months) of runway, although this could shorten as spending increases to commercialise its battery technologies; importantly, ADO had no bank debt at year-end.

In other words, the balance sheet is in much better shape following the option exercise, but ADO remains a cash-burning, pre-commercial business and ultimately needs meaningful customer revenues to reduce its reliance on external capital.

ADO’s key differentiator is its proprietary binding chemistry, designed to improve performance while reducing cost and manufacturing complexity. In Life Sciences, AnteoBind reduces antibody usage and processing times, while its battery technologies target higher energy density, improved silicon-anode durability and PFAS-free manufacturing using existing production processes. The key hurdle remains converting these technical advantages into meaningful commercial contracts.

The battery arm, the growth lever and reason to own ADO, has yet to convert its pipeline of trials and joint development agreements into a confirmed commercial supply contract — any such deal would be a material re-rating catalyst given the addressable market.

  • It’s not one for MM yet but could prove interesting over time.
chart
image description
Anteotech Ltd (ADO)
image description

Relevant suggested news and content from the site

Back to top